Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System
ConclusionsOur study comprehensively analyzed the toxicity profiles of anti-GD2 monoclonal antibodies and provides an important reference for clinical monitoring and ADR identification of these drugs. (Source: Pediatric Drugs)
Source: Pediatric Drugs - December 28, 2023 Category: Pediatrics Source Type: research
Acknowledgement to Referees
(Source: Pediatric Drugs)
Source: Pediatric Drugs - December 21, 2023 Category: Pediatrics Source Type: research
Managing Lupus Nephritis in Children and Adolescents
AbstractLupus nephritis is an important manifestation of systemic lupus erythematosus, which leads to chronic kidney disease, kidney failure, and can result in mortality. About 35% –60% of children with systemic lupus erythematosus develop kidney involvement. Over the past few decades, the outcome of patients with lupus nephritis has improved significantly with advances in immunosuppressive therapies and clinical management. Nonetheless, there is a paucity of high-level evid ence to guide the management of childhood-onset lupus nephritis, because of the relatively small number of patients at each centre and also because ...
Source: Pediatric Drugs - December 20, 2023 Category: Pediatrics Source Type: research
Incidence of Antimicrobial-Associated Acute Kidney Injury in Children: A Structured Review
In conclusion, antimicrobial-associated AKI is reported to occur frequently in children, but the rates of AKI varies widely a cross studies and drugs. Most published studies examined hospitalized patients and heterogeneity in study populations and in author definitions of AKI are barriers to a comparison of nephrotoxicity risk among antimicrobials in children. (Source: Pediatric Drugs)
Source: Pediatric Drugs - December 13, 2023 Category: Pediatrics Source Type: research
Bosutinib: Pediatric First Approval
This article summarizes the milestones in the development of bosutinib leading to this first pediatric approval. (Source: Pediatric Drugs)
Source: Pediatric Drugs - December 7, 2023 Category: Pediatrics Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
AbstractRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis ™–AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that include vaccines and long-acting, high-potency monoclonal antibodies. Ni rsevimab (Beyf...
Source: Pediatric Drugs - November 30, 2023 Category: Pediatrics Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. (Source: Pediatric Drugs)
Source: Pediatric Drugs - November 25, 2023 Category: Pediatrics Source Type: research
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach
ConclusionsMinimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.Trial RegistrationClinicalTrials.gov Identifier: NCT04459117. (Source: Pediatric Drugs)
Source: Pediatric Drugs - November 17, 2023 Category: Pediatrics Source Type: research
Emerging Treatments for Childhood Interstitial Lung Disease
This article summarizes current treatments and explores potential therapeutic options for patients suffering from chILD. (Source: Pediatric Drugs)
Source: Pediatric Drugs - November 10, 2023 Category: Pediatrics Source Type: research
Practical Questions About Rescue Medications for Acute Treatment of Seizure Clusters in Children and Adolescents with Epilepsy in the USA: Expanding Treatment Options to Address Unmet Needs
AbstractEpilepsy is a common pediatric neurological condition, affecting approximately 470,000 children in the USA and having a prevalence of 0.9% in the global population of approximately 2.6 billion children. Epilepsy is associated with disruptions in several areas of a child ’s life, including medical burden, quality of life, cognitive outcomes, and higher risk of mortality. Additionally, some pediatric patients may experience acute seizure emergencies such as seizure clusters (also called acute repetitive seizures), which are intermittent increases in seizure activit y that differ from the patient’s usual seizure p...
Source: Pediatric Drugs - October 30, 2023 Category: Pediatrics Source Type: research
Correction to: Viloxazine: Pediatric First Approval
(Source: Pediatric Drugs)
Source: Pediatric Drugs - October 20, 2023 Category: Pediatrics Source Type: research
Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies
AbstractPsoriasis is a chronic immune-mediated disorder that commonly affects adults and children. In recent years, pediatric psoriasis has increased in prevalence and the disease is often associated with various comorbidities and psychological distress. The conventional topical treatments for psoriasis, such as corticosteroids, calcineurin inhibitors, vitamin D analogs, anthralin, and coal tar, are often limited by their side effects, tolerability, and/or efficacy, particularly for use in children and on sensitive and intertriginous areas. Recently, the US Food and Drug Administration approved two new topical non-steroida...
Source: Pediatric Drugs - October 17, 2023 Category: Pediatrics Source Type: research
Pediatric Drugs, Accelerated Approval, and Prospects for Reform
(Source: Pediatric Drugs)
Source: Pediatric Drugs - October 14, 2023 Category: Pediatrics Source Type: research
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants
This article summarizes the milestones in the development of RSVpreF leading to the approval for use in pregnant individuals to prevent LRTD in infants. (Source: Pediatric Drugs)
Source: Pediatric Drugs - October 13, 2023 Category: Pediatrics Source Type: research
Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients
AbstractUveitis in children accounts for 5 –10% of all cases. The causes vary considerably. Classically, uveitis is distinguished according to its infectious or inflammatory origin and whether it is part of a systemic disease or represents an isolated ocular disease. It is important to highlight the specificity of certain etiologies among children such as juvenile idiopathic arthritis. The development of visual function can potentially be hindered by amblyopia (children aged< 7 years), in addition to the usual complications (synechiae, macular edema) seen in adult patients. Moreover, the presentation of uveitis in ...
Source: Pediatric Drugs - October 4, 2023 Category: Pediatrics Source Type: research
